

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application: Hoon HAN *et al.*

U.S. Application No.: 10/579,071

Confirmation No. 3306

Filed: May 11, 2006

Title: METHOD OF ISOLATING AND  
CULTURING MESENCHYMAL STEM  
CELL DERIVED FROM CRYOPRESERVED  
UMBILICAL CORD BLOOD

Art Unit: 1651

Examiner: Ruth A. DAVIS

Atty. Docket No.: 36470-231117

Customer No.

26694  
PATENT TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of **Document C1** is enclosed, which is an Office Action issued in the related application 10/579,070. The only references mentioned that have not previously been cited are Petaja *et al.*, Journal of Clinical Investigations 1997, 99: 2655-2663 (page 3) and Goodwin *et al.*, Blood, Bone, and Marrow Transplant 2001, 7: 581-588 (page 7), copies of which are enclosed for reference.

The instant Information Disclosure Statement is filed after the mailing date of a Notice of Allowance but before the payment of the Issue Fee, pursuant to 37 CFR 1.97(d). Applicants hereby petition that the Information Disclosure Statement be considered and a fee of \$180.00 is attached.

I hereby certify, pursuant to 37 CFR 1.97(e)(2), that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

We believe that no additional fees are required with the submission of this IDS. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be

filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 36470-231117.

Respectfully submitted,

Dated: July 16, 2009

/Keith G. Haddaway/

Keith G. Haddaway, Ph.D.  
Registration No. 46,180  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
202-344-8009  
202-344-8300 (fax)

DC2/1041554